Unexpected toxicity and safety issues constitute one of the most disruptive events in drug R&D, with one third of drug attrition still directly related to these events. In this context, a translational approach to drug safety and prompt access to actionable safety intelligence can significantly reduce patient burden and avoid costly failures.
Since 2017, the Bioinfogate OFF-XTM portal has been supporting translational researchers in pharmaceutical and healthcare organizations to de-risk drug R&D programs.
Rapid access to actionable safety intelligence via OFF-X provides a critical competitive advantage for your R&D:
- Time saving: OFF-X reduces the time and resources required to retrieve critical safety intelligence. OFF-X breaks information silos by comprehensively integrating disparate sources of data with a fast turnaround.
- Comprehensiveness: OFF-X’s extensive coverage of information sources provides daily access to key data that is not readily available and that may not be published elsewhere after a first mention, for example a reference in a scientific congress.
- OFF-X covers all phases of drug R&D, including first-in-class and emerging targets.
- OFF-X provides a unique translational approach: used across a wide range of departments and facilitates the translational safety intelligence paradigm by interconnecting and integrating critical safety intelligence form early target discovery to post-marketing and patient safety.
Contact us today to arrange a demonstration and request a 2 week trial
Bioinfogate, part of Clarivate, is a forward-thinking team working to solve unmet medical needs. Bioinfogate helps companies, academic institution, and government and regulatory agencies working in scientific and research and drug R&D. Our innovative knowledge management tools and analytics software solutions support the discovery and development of better and safer drugs.
Our passion and capabilities stem from more than 60 years’ experience creating and managing biomedical knowledge, first as ProusScience (acquired by Thomson Reuters in 2007), and then as the Prous Institute for Biomedical Research. Bioinfogate was acquired by Clarivate in 2021 to advance the next generation of life sciences analytics solutions, and embracing a long tradition of expertise in scientific knowledge management.